Carisma Therapeutics Inc.
DelistedCIK 1485003fmd_0TAVK5DAWFFCJXEWM6N0RF21KQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2025, 52 periods
Latest annual · FY2024
Millions- Total revenues
- 20
- Operating income
- (62)
- Net income
- (60)
- Free cash flow
- (60)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 45
- Operating income
- 44
- Net income
- 45
- Free cash flow
- 2
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- -9.6%
- Revenue, 5 yearsFY2019 to FY2024
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
Carisma Therapeutics Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $19.6 million | $14.9 million | +31.5% | 10-K 2025-03-31 · proof |
| Operating income | -$62.2 million | -$88.7 million | 10-K 2025-03-31 · proof | |
| Net income | -$60.5 million | -$86.9 million | 10-K 2025-03-31 · proof | |
| Cash from operating activities | -$59.9 million | -$81.2 million | 10-K 2025-03-31 · proof | |
| Free cash flow | -$60 million | -$82.3 million | 10-K 2025-03-31 · proof | |
| Total assets | $30.5 million | $89.6 million | -66% | 10-K 2025-03-31 · proof |
| Total liabilities | $58.4 million | $63 million | -7.4% | 10-K 2025-03-31 · proof |
| Cash and cash equivalents | $17.9 million | $77.6 million | -76.9% | 10-K 2025-03-31 · proof |
- What was Carisma Therapeutics Inc.'s revenue in fiscal 2024?
- Carisma Therapeutics Inc. reported revenue of $19.6 million for fiscal 2024 (the year ended Dec 31, 2024), against $14.9 million the year before (+31.5%). Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What was Carisma Therapeutics Inc.'s operating income in fiscal 2024?
- Carisma Therapeutics Inc. reported operating income of -$62.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$88.7 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What was Carisma Therapeutics Inc.'s net income in fiscal 2024?
- Carisma Therapeutics Inc. reported net income of -$60.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$86.9 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What was Carisma Therapeutics Inc.'s cash from operating activities in fiscal 2024?
- Carisma Therapeutics Inc. reported cash from operating activities of -$59.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$81.2 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What was Carisma Therapeutics Inc.'s free cash flow in fiscal 2024?
- Carisma Therapeutics Inc. reported free cash flow of -$60 million for fiscal 2024 (the year ended Dec 31, 2024), against -$82.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What are Carisma Therapeutics Inc.'s total assets?
- As of Dec 31, 2024, Carisma Therapeutics Inc. reported total assets of $30.5 million, against $89.6 million a year earlier (-66%). Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What are Carisma Therapeutics Inc.'s total liabilities?
- As of Dec 31, 2024, Carisma Therapeutics Inc. reported total liabilities of $58.4 million, against $63 million a year earlier (-7.4%). Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
- What are Carisma Therapeutics Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Carisma Therapeutics Inc. reported cash and cash equivalents of $17.9 million, against $77.6 million a year earlier (-76.9%). Source: the 10-K filed with the SEC on Mar 31, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1485003&period_type=annual&limit=5"Information only, not investment advice.